Goebeler, M., & Nagorsen, D. (2016). Bispecific T-cell engager (BiTE) antibody construct blinatumomab for the treatment of patients with relapsed/refractory non-hodgkin lymphoma: Final results from a phase I study. Journal of clinical oncology, 34(10), . https://doi.org/10.1200/JCO.2014.59.1586
Chicago-Zitierstil (17. Ausg.)Goebeler, Maria-Elisabeth, und Dirk Nagorsen. "Bispecific T-cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients with Relapsed/refractory Non-hodgkin Lymphoma: Final Results from a Phase I Study." Journal of Clinical Oncology 34, no. 10 (2016). https://doi.org/10.1200/JCO.2014.59.1586.
MLA-Zitierstil (9. Ausg.)Goebeler, Maria-Elisabeth, und Dirk Nagorsen. "Bispecific T-cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients with Relapsed/refractory Non-hodgkin Lymphoma: Final Results from a Phase I Study." Journal of Clinical Oncology, vol. 34, no. 10, 2016, https://doi.org/10.1200/JCO.2014.59.1586.